PBM Price Transparency and Accountability Act
The PBM Price Transparency and Accountability Act requires pharmacy benefit managers (PBMs) to be more transparent about drug pricing and ensure accurate payments to pharmacies. It establishes national average drug acquisition cost benchmarks for Medicaid, prohibits PBMs from keeping excessive profits through "spread pricing," and mandates detailed reporting of drug pricing, rebates, and fees. The bill affects Medicaid programs, Medicare Part D plans, and the PBMs that negotiate drug prices on behalf of insurers. It includes enforcement mechanisms like civil penalties for non-compliance and requires PBMs to report detailed pricing information to the Secretary of Health and Human Services.
Bill status
in committee
1 of 4 stages cleared
Introduction
Dec 2025
Committee Review
Floor Vote
President
Introduced Dec 4, 2025
Last action Dec 4, 2025
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Dec 4, 2025
Committee
Read twice and referred to the Committee on Finance.
upper
Dec 4, 2025
Introduced
Introduced in Senate
upper
1 primary · 27 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Mike Crapo
RRepublican
Co
Ben Ray Luján
DDemocratic
Co
Bill Cassidy
RRepublican
Co
Catherine Cortez Masto
DDemocratic
Co
Chuck Grassley
RRepublican
Co
David McCormick
RRepublican
Co
James E. Risch
RRepublican
Co
James Lankford
RRepublican
Co
John Barrasso
RRepublican
Co
John Cornyn
RRepublican
Co
John Thune
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about S 3345
Scope: US
Hi! I can help you understand S 3345. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline